All Mark Klempner articles
-
NewsPhase I study for human monoclonal antibody for Lyme disease demonstrates safety, tolerability, pharmacokinetics
A Phase I clinical trial of a human monoclonal antibody discovered and developed for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum concentrations in participants, according to data.